The high proportion of activated DCs and increased expression of markers associated with T cell attraction and activation following KRAS-G12C inhibition, as well as evidence for local tumor cell death, pointed toward the T/DC community as a potential cytotoxic T cell activation hub. The gene discussed is KRAS; the disease is neoplasm.